新型冠状病毒与眼科相关研究进展

doi:10.6040/j.issn.1673-3770.0.2022.515

摘要/Abstract

摘要： 新型冠状病毒感染(corona virus disease 2019,COVID-19)是由严重急性呼吸综合征冠状病毒-2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的急性感染性肺炎。目前临床已有较多病例报告提示COVID-19患者也可表现出眼部症状,同时在新型冠状病毒疫苗的应用过程中亦出现了各种眼部不良事件。论文通过回顾国内外相关文献及研究,探讨SARS-CoV-2经眼传播的可能性、眼部受累表现、治疗方案以及接种COVID-19疫苗后可能出现的眼部不良事件,并为眼科医务人员的临床防护给出建议。

关键词: 新型冠状病毒感染, 结膜炎, 视网膜血管病变, 脉络膜, 闭角型青光眼

Abstract: Corona virus disease 2019(COVID-19)is an acute infectious pneumonia caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Previous reports have suggested that patients with COVID-19 may also exhibit ocular symptoms, and some ophthalmic adverse events have been reported after COVID-19 vaccination. Based on the recent literature and existing studies, this study aims to discuss the possibility of ophthalmic infections due to SARS-CoV-2, the ocular signs, treatments and possible ocular adverse events after COVID-19 vaccination, and provide references to the ophthalmologists for prevention and control.

Key words: Corona virus disease 2019, Conjunctivitis, Retinal vasculopathy, Choroid, Angle-closure glaucoma

中图分类号:

丁晓敏,崔彦. 新型冠状病毒与眼科相关研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 122-127.

DING Xiaomin, CUI Yan. Advances in severe acute respiratory syndrome coronavirus 2 study about ophthalmology[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(1): 122-127.

参考文献

[1] Chen NS, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513. doi:10.1016/S0140-6736(20)30211-7
[2] Lu HZ, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle[J]. J Med Virol, 2020, 92(4): 401-402. doi:10.1002/jmv.25678
[3] Wu P, Duan F, Luo CH, et al. Characteristics of ocular findings of patients with coronavirus disease 2019(COVID-19)in Hubei Province, China[J]. JAMA Ophthalmol, 2020, 138(5): 575-578. doi:10.1001/jamaophthalmol.2020.1291
[4] Ocansey S, Abu EK, Abraham CH, et al. Ocular symptoms of SARS-CoV-2: indication of possible ocular transmission or viral shedding[J]. Ocul Immunol Inflamm, 2020, 28(8): 1269-1279. doi:10.1080/09273948.2020.1799035
[5] Xia JH, Tong JP, Liu MY, et al. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection[J]. J Med Virol, 2020, 92(6): 589-594. doi:10.1002/jmv.25725
[6] Belser JA, Rota PA, Tumpey TM. Ocular tropism of respiratory viruses[J]. Microbiol Mol Biol Rev, 2013, 77(1): 144-156. doi:10.1128/MMBR.00058-12
[7] Seah I, Agrawal R. Can the coronavirus disease 2019(COVID-19)affect the eyes? A review of coronaviruses and ocular implications in humans and animals[J]. Ocul Immunol Inflamm, 2020, 28(3): 391-395. doi:10.1080/09273948.2020.1738501
[8] 季樱红, 孙杨, 卢奕. 新型冠状病毒的眼睛侵入途径与眼科防护重点[J]. 中国眼耳鼻喉科杂志, 2020, 20(3): 156-161.doi: 10.14166/j.issn.1671-2420.2020.03.003 JI Yinghong, SUN Yang, LU Yi. Eye invasion route of 2019 novel corona virus and the emphasis of ophthalmic protection[J]. Chinese Journal of Ophthalmology and otorhinolaryngology, 2020, 20(3): 156-161.doi: 10.14166/j.issn.1671-2420.2020.03.003
[9] Imai Y, Kuba K, Ohto-Nakanishi T, et al. Angiotensin-converting enzyme 2(ACE2)in disease pathogenesis[J]. Circ J, 2010, 74(3): 405-410. doi:10.1253/circj.cj-10-0045
[10] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature, 2003, 426(6965): 450-454. doi: 10.1038/nature02145
[11] Deng W, Bao LL, Gao H, et al. Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques[J]. Nat Commun, 2020, 11(1): 4400. doi:10.1038/s41467-020-18149-6
[12] Hui KPY, Cheung MC, Perera RAPM, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures[J]. Lancet Respir Med, 2020, 8(7): 687-695. doi:10.1016/S2213-2600(20)30193-4
[13] Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study[J]. Lancet, 2022, 399(10335): 1618-1624. doi:10.1016/S0140-6736(22)00327-0
[14] Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply[J]. N Engl J Med, 2020, 382(19): 1861-1862. doi:10.1056/NEJMc2005203
[15] Wu P, Liang L, Chen CB, et al. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis[J]. Graefes Arch Clin Exp Ophthalmol, 2020, 258(7): 1565-1566. doi:10.1007/s00417-020-04708-6
[16] Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2[J]. Am J Ophthalmol Case Rep, 2020, 19: 100735. doi:10.1016/j.ajoc.2020.100735
[17] Méndez Mangana C, Barraquer Kargacin A, Barraquer RI. Episcleritis as an ocular manifestation in a patient with COVID-19[J]. Acta Ophthalmol, 2020, 98(8): e1056-e1057. doi:10.1111/aos.14484
[18] François J, Collery AS, Hayek G, et al. Coronavirus disease 2019-associated ocular neuropathy with panuveitis: a case report[J]. JAMA Ophthalmol, 2021, 139(2): 247-249. doi:10.1001/jamaophthalmol.2020.5695
[19] Providência J, Fonseca C, Henriques F, et al. Serpiginous choroiditis presenting after SARS-CoV-2 infection: a new immunological trigger?[J]. Eur J Ophthalmol, 2022, 32(1): NP97-NP101. doi:10.1177/1120672120977817
[20] Casagrande M, Fitzek A, Püschel K, et al. Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients[J]. Ocul Immunol Inflamm, 2020, 28(5): 721-725. doi:10.1080/09273948.2020.1770301
[21] de Figueiredo CS, Raony í, Giestal-de-Araujo E. SARS-CoV-2 targeting the retina: host-virus interaction and possible mechanisms of viral tropism[J]. Ocul Immunol Inflamm, 2020, 28(8): 1301-1304. doi:10.1080/09273948.2020.1799037
[22] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418. doi:10.1016/S0140-6736(20)30937-5
[23] Marinho PM, Marcos AAA, Romano AC, et al. Retinal findings in patients with COVID-19[J]. Lancet, 2020, 395(10237): 1610. doi:10.1016/S0140-6736(20)31014-X
[24] Invernizzi A, Torre A, Parrulli S, et al. Retinal findings in patients with COVID-19: results from the SERPICO-19 study[J]. EClinicalMedicine, 2020, 27: 100550. doi:10.1016/j.eclinm.2020.100550
[25] Sheth JU, Narayanan R, Goyal J, et al. Retinal vein occlusion in COVID-19: a novel entity[J]. Indian J Ophthalmol, 2020, 68(10): 2291-2293. doi:10.4103/ijo.IJO_2380_20
[26] Ortiz-Seller A, Martínez Costa L, Hernández-Pons A, et al. Ophthalmic and neuro-ophthalmic manifestations of coronavirus disease 2019(COVID-19)[J]. Ocul Immunol Inflamm, 2020, 28(8): 1285-1289. doi:10.1080/09273948.2020.1817497
[27] Benito-Pascual B, Gegúndez JA, Díaz-Valle D, et al. Panuveitis and optic neuritis as a possible initial presentation of the novel coronavirus disease 2019(COVID-19)[J]. Ocul Immunol Inflamm, 2020, 28(6): 922-925. doi:10.1080/09273948.2020.1792512
[28] 中华预防医学会公共卫生眼科学分会. 中国新型冠状病毒眼病防控专家共识(2022年)[J]. 中华眼科杂志, 2022, 58(3): 176-181. doi: 10.3760/cma.j.cn112142-20211124-00561
[29] Luís ME, Hipólito-Fernandes D, Mota C, et al. A review of neuro-ophthalmological manifestations of human coronavirus infection[J]. Eye Brain, 2020, 12: 129-137. doi:10.2147/EB.S268828
[30] Tisdale AK, Chwalisz BK. Neuro-ophthalmic manifestations of coronavirus disease 19[J]. Curr Opin Ophthalmol, 2020, 31(6): 489-494. doi:10.1097/ICU.0000000000000707
[31] Ordás CM, Villacieros-álvarez J, Pastor-Vivas AI, et al. Concurrent tonic pupil and trochlear nerve palsy in COVID-19[J]. J Neurovirol, 2020, 26(6): 970-972. doi:10.1007/s13365-020-00909-1
[32] 胡明霞, 袁建明, 张彬, 等. 新型冠状病毒疫苗的研究进展[J]. 中国感染与化疗杂志, 2022, 22(4): 504-508. doi: 10.16718/j.1009-7708.2022.04.023 HU Mingxia, YUAN Jianming, ZHANG Bin, et al. Research updates on SARS-CoV-2 vaccines[J]. Chinese Journal of Infection and Chemotherapy, 2022, 22(4): 504-508. doi: 10.16718/j.1009-7708.2022.04.023
[33] Haseeb AA, Solyman O, Abushanab MM, et al. Ocular complications following vaccination for COVID-19: a one-year retrospective[J]. Vaccines(Basel), 2022, 10(2): 342. doi:10.3390/vaccines10020342
[34] Sheng QL, Sun YN, Zhai RY, et al. Posner-Schlossman syndrome relapse following inactivated COVID-19 vaccination in China[J]. Front Public Health, 2022, 10: 1051378. doi:10.3389/fpubh.2022.1051378
[35] Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports[J]. Cutan Ocul Toxicol, 2010, 29(1): 26-29. doi:10.3109/15569520903427717
[36] Aguirre G, Carmichael L, Bistner S. Corneal endothelium in viral induced anterior uveitis. Ultrastructural changes following canine adenovirus type 1 infection[J]. Arch Ophthalmol, 1975, 93(3): 219-224. doi:10.1001/archopht.1975.01010020227012
[37] Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis after the bnt162b2 mrna vaccination against sars-cov-2 infection: a possible association[J]. Retina, 2021, 41(12): 2462-2471. doi:10.1097/IAE.0000000000003277
[38] Steinemann TL, Koffler BH, Jennings CD. Corneal allograft rejection following immunization[J]. Am J Ophthalmol, 1988, 106(5): 575-578. doi:10.1016/0002-9394(88)90588-0
[39] Abousy M, Bohm K, Prescott C, et al. Bilateral EK rejection after COVID-19 vaccine[J]. Eye Contact Lens, 2021, 47(11): 625-628. doi:10.1097/ICL.0000000000000840
[40] Bøhler AD, Strøm ME, Sandvig KU, et al. Acute macular neuroretinopathy following COVID-19 vaccination[J]. Eye(Lond), 2022, 36(3): 644-645. doi: 10.1038/s41433-021-01610-1
[41] Pichi F, Aljneibi S, Neri P, et al. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in abu dhabi[J]. JAMA Ophthalmol, 2021, 139(10): 1131-1135. doi: 10.1001/jamaophthalmol.2021.3477
[42] Mambretti M, Huemer J, Torregrossa G, et al. Acute macular neuroretinopathy following coronavirus disease 2019 vaccination[J]. Ocul Immunol Inflamm, 2021, 29(4): 730-733. doi:10.1080/09273948.2021.1946567
[43] Elnahry AG, Al-Nawaflh MY, Gamal Eldin AA, et al. COVID-19 vaccine-associated optic neuropathy: a systematic review of 45 patients[J]. Vaccines(Basel), 2022, 10(10): 1758. doi:10.3390/vaccines10101758
[44] Eleiwa TK, Gaier ED, Haseeb A, et al. Adverse ocular events following COVID-19 vaccination[J]. Inflamm Res, 2021, 70(10/11/12): 1005-1009. doi:10.1007/s00011-021-01506-6
[45] Tsukii R, Kasuya Y, Makino S. Nonarteritic anterior ischemic optic neuropathy following COVID-19 vaccination: consequence or coincidence[J]. Case Rep Ophthalmol Med, 2021: 5126254. doi:10.1155/2021/5126254
[46] 陈博, 张宪, 孙旭芳. 新型冠状病毒防控中眼科医务人员的预防措施[J]. 国际眼科杂志, 2020, 20(3): 580-582. doi: 10.3980/j.issn.1672-5123.2020.3.41 CHEN Bo, ZHANG Xian, SUN Xufang. Precaution of SARS-CoV-2 infection in ophthalmology medical staff[J]. International Eye Science, 2020, 20(3): 580-582. doi: 10.3980/j.issn.1672-5123.2020.3.41
[47] Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents[J]. J Hosp Infect, 2020, 104(3): 246-251. doi:10.1016/j.jhin.2020.01.022
[48] Du H, Zhang M, Zhang H, et al. Practical experience on emergency ophthalmic surgery during the prevalence of COVID-19[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2020, 258(8): 1831-1833. doi:10.1007/s00417-020-04692-x
[49] Yu AY, Tu RX, Shao X, et al. A comprehensive Chinese experience against SARS-CoV-2 in ophthalmology[J]. Eye Vis(Lond), 2020, 7: 19. doi:10.1186/s40662-020-00187-2
[50] Güemes-Villahoz N, Burgos-Blasco B, Vidal-Villegas B, et al. Novel insights into the transmission of SARS-CoV-2 through the ocular surface and its detection in tears and conjunctival secretions: a review[J]. Adv Ther, 2020, 37(10): 4086-4095. doi:10.1007/s12325-020-01442-7

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed